VRCA Verrica Pharmaceuticals Inc.

15.29
-1.57  -9%
Previous Close 16.86
Open 17
Price To Book 5.5
Market Cap 394,102,258
Shares 25,775,164
Volume 123,899
Short Ratio
Av. Daily Volume 78,854
Stock charts supplied by TradingView

NewsSee all news

  1. Verrica Pharmaceuticals Announces Presentation of Positive Data from New Pooled Analysis of Phase 3 CAMP Trials of VP-102

    - Analysis suggested statistically significantly higher lesion clearance with VP-102 compared to vehicle in all regions of the body, including those deemed most sensitive - - If approved, VP-102 will be marketed in

  2. Verrica Pharmaceuticals Announces FDA Filing Acceptance of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

    - PDUFA date assigned is July 13, 2020 - - VP-102 (cantharidin 0.7% Topical Solution) could potentially be the first FDA-approved treatment for molluscum contagiosum, a highly contagious viral skin infection affecting

  3. Verrica Pharmaceuticals Announces Participation in the Piper Jaffray 31st Annual Healthcare Conference

    WEST CHESTER, Pa., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that

  4. Verrica Pharmaceuticals Announces Passing of Board of Directors Member Glenn Oclassen

    WEST CHESTER, Pa., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), announces with deep sadness the passing of Glenn Oclassen, a valued member of the Company's Board of

  5. Verrica Pharmaceuticals Reports Third Quarter 2019 Financial Results

    -Submitted New Drug Application to U.S. Food and Drug Administration for VP-102 for the treatment of molluscum contagiosum -Presented three abstracts at the Fall Clinical Dermatology Conference, including two analyses

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

PDUFA date July 13, 2020.
VP-102
Molluscum contagiosum
Phase 3 trial to be initiated 1Q 2020.
VP-102
Common warts
Phase 2 data due 2H 2020
VP-102
Genital warts

Latest News

  1. Verrica Pharmaceuticals Announces Presentation of Positive Data from New Pooled Analysis of Phase 3 CAMP Trials of VP-102

    - Analysis suggested statistically significantly higher lesion clearance with VP-102 compared to vehicle in all regions of the body, including those deemed most sensitive - - If approved, VP-102 will be marketed in

  2. Verrica Pharmaceuticals Announces FDA Filing Acceptance of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

    - PDUFA date assigned is July 13, 2020 - - VP-102 (cantharidin 0.7% Topical Solution) could potentially be the first FDA-approved treatment for molluscum contagiosum, a highly contagious viral skin infection affecting

  3. Verrica Pharmaceuticals Announces Participation in the Piper Jaffray 31st Annual Healthcare Conference

    WEST CHESTER, Pa., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that

  4. Verrica Pharmaceuticals Announces Passing of Board of Directors Member Glenn Oclassen

    WEST CHESTER, Pa., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), announces with deep sadness the passing of Glenn Oclassen, a valued member of the Company's Board of

  5. Verrica Pharmaceuticals Reports Third Quarter 2019 Financial Results

    -Submitted New Drug Application to U.S. Food and Drug Administration for VP-102 for the treatment of molluscum contagiosum -Presented three abstracts at the Fall Clinical Dermatology Conference, including two analyses

  6. Verrica Pharmaceuticals Announces Presentation of Positive Data from Clinical Trials of VP-102 at the 2019 39th Annual Fall Clinical Dermatology Conference

    Pooled analyses of the Phase 3 CAMP studies in molluscum contagiosum showed VP-102 achieved statistically significantly higher rate of complete lesion clearance and percentage of subjects with > 75% and > 90%

  7. Verrica Pharmaceuticals Appoints Eugene Scavola to the Position of Executive Vice President, Technical Operations

    WEST CHESTER, Pa., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that

  8. Verrica Pharmaceuticals Announces Leadership Team Update

    WEST CHESTER, Pa., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that

  9. Verrica Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for VP-102 for the Treatment of Molluscum Contagiosum

    WEST CHESTER, Pa., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that

  10. Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 21st Annual Global Investment Conference

    WEST CHESTER, Pa., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that